Introduction
Positron emission tomography (PET) provides unique insights into molecular pathways of diseases. PET, especially when combined with computed tomography (PET/CT), is the most advanced technique for metabolic imaging and one of the most accurate tools for tumor staging in the pretreatment, posttreatment, and follow-up phases of many malignant tumors. The most commonly used metabolic tracer for PET in oncology is 18 F-fluorodeoxyglucose (FDG). FDG is an analogue of glucose that is taken up, phosphorylated, and trapped inside metabolically active, proliferating cells. In prostate cancer, however, the use of 18 F-FDG PET has been limited mainly due to the low uptake of FDG and urinary excretion of the tracer. Recently, novel PET tracers with more favorable properties are being tested in clinical studies leading to increased application of PET/CT in prostate cancer [1 ] .
Advances in radiopharmaceuticals have resulted in the introduction of new useful therapeutic agents in the clinical management of cancer patients. In targeted therapy, selective molecules are used for tumor-specific delivery of the anticancer drugs and, thereby, limiting the damage to healthy tissues. The novel class of radiopharmaceuticals combined with molecular imaging of their targets offers the potential to develop patient-specific therapies. During the last decade, application of radiolabeled peptides and antibodies for endoradiotherapy have been extensively tested, and some of these drugs such as 90 Y-ibritumomab tiuxetan (Zevalin, Bayer Schering Pharma, Berlin, Germany), 131 I-tositumomab (Bexxar, GlaxoSmithKline, Philadelphia, Pennsylvania, USA), and the somatostatin receptor-binding 90 
Positron emission tomography/computed tomography
The most common PET tracers used for detection of prostate cancer are 11 C-acetate, 11 C-choline, and 18 Ffluorocholine (FCH) [1 ,4-6] . Recently, acetate has also been labeled with 18 F, that is, 18 F-fluoroacetate [7] . Choline is a component of the phosphatidylcholines, a class of phospholipids and a major component of biologic membranes. Prostate cancer is characterized by upregulated choline kinase activity and increased choline uptake [8] . Therefore, malignant tumors of the prostate show increased metabolism of cell membrane components resulting in a relatively high uptake of choline as compared with less aggressive neoplasms. Acetate is a substrate for the tricarboxylic acid (TCA) cycle [9 ,10] . Cellular uptake of 11 C-acetate is proportional to lipid synthesis, and increased fatty acid synthesis has been demonstrated in prostate cancer [8, 10] . In a direct comparison of 11 C-choline and 11 C-acetate, Kotzerke et al. [11] demonstrated that both tracers performed nearly identically in prostate cancer patients.
Primary diagnosis
Li et al. [12 ] investigated 49 patients for the potential of 11 C-choline PET/CT imaging for differentiating prostate cancer from benign prostatic hyperplasia (BPH). PET data were analyzed visually and semiquantitatively by measuring maximum standardized uptake value (SUV max ) in the prostate lesions (target) and in the muscles (nontarget), and calculating their ratios (P/M). Using 2.3 (P/M) as the criterion, 11 C-choline PET/CT imaging showed a sensitivity of 90.48%, a specificity of 85.71%, and a negative predictive value of 92.31%. These results suggest that the parameter P/M could differentiate prostate cancer from benign lesions better than SUV. Kwee et al. [13 ] 11 C-choline PET/CT and radical prostatectomy with extended pelvic lymph node dissection. Risk of lymph node metastasis was assessed using available nomograms. The authors found that the sensitivity and specificity of correctly recognized cases with 11 C-choline PET/CT were 60.0 and 97.6%, respectively, whereas on a lesional-based (lymph node) analysis, these numbers were 41.4 and 99.8%.
11 C-choline PET/CT for lymph node metastases detection performed better than clinical nomograms, with equal sensitivity and better specificity. Husarik et al. [17] used 18 F-FCH PET/CT for correlation with lymphadenectomy for initial N-staging. Histopathological work-up was performed on 115 lymph nodes sampled from 25 patients. Only one of these lymph nodes showed pathological 18 F-FCH accumulation and was proven to be a metastasis measuring more than 1 cm. Four lymph nodes that did not show 18 F-FCH accumulation turned out to contain metastatic cells, with an overall tumor load measuring less than 0.5 cm. The results obtained using 18 F-FCH PET/CT for initial N-staging were discouraging, especially in terms of its inability to detect small metastases (micrometastases). The role of PET/CT in N-staging remains to be evaluated in larger clinical trials.
Recurrence
Rinnab et al. [18] investigated the diagnostic value of 11 C-choline PET/CT in patients with suspected lymph node metastases before salvage lymph node dissection in 15 consecutive patients with rising PSA. In this study, 11 C-choline was found useful for targeted salvage lymph node dissection. However, the presented cohort was limited in size. In another small study by Schilling et al. [19] , 11 C-choline PET/CT was found useful for detection of recurrence of prostate cancer. However, a limited positive predictive value (PPV) for locating pelvic lymph node metastases in recurrent prostate cancer was found. Reske et al. [20 ] assessed the value of 11 C-choline PET/CT for localizing occult relapse after radical prostatectomy in 49 patients; 13 patients served as controls (mean PSA 0.10 ng/ml, clinically unremarkable follow-up after 1 year). PET/CT was judged negative for local remission in 12 of 13 of the controls. The other group consisted of 36 men who were suspected to have occult relapse of prostate cancer (mean PSA 2.0 ng/ml). In this group, PET/CT showed true positive focal lesions with increased 11 C-choline uptake in 70% (23/33) of the patients with histological verification of local recurrence.
Tuncel et al. [21] reported that 11 C-choline PET/CT (low-dose CT) resulted in improved lesion localization and changed disease management in 11 (24%) of 45 patients with advanced prostate cancer. Krause et al. [22 ] assessed the relationship between the detection rate of 11 C-choline PET/CT and PSA level in 63 patients with biochemical recurrence after primary therapy. The detection rate was 36% for a PSA value less than 1 ng/ml, 43% for a PSA value 1 to less than 2 ng/ml, 62% for a PSA value 2 to less than 3 ng/ml, and 73% for a PSA value of at least 3 ng/ml. Thus, the detection rate depended on serum PSA level. Tc-methylene diphosphonate (MDP) is still used as the most common imaging technique to detect bone metastases in prostate cancer patients. However, this technique does not differentiate between the metastatic and benign processes in the bones. PET/CT with 18 F-fluoride seems to be superior to MDP bone scan for detection of bone metastases [23, 24] . Fluoride uptake depends on regional blood flow and in particular on local osteoblastic activity [8, 25 ]. In a prospective study, Beheshti et al. [25 ] C-choline PET/CT seemed to be equally effective as diffusionweighted MRI in detection of bone metastases. However, this finding needs to be confirmed in larger trials.
Radioimmunotherapy
Endoradiotherapy using peptides or antibodies combines the favorable targeting properties with the effect of radiation-induced cell death. In endoradiotherapy, smaller amounts of drug can be applied as compared with other forms of cancer therapy. Furthermore, these drugs can not only be labeled with therapeutic nuclides but also with diagnostic ones. Thus, it is possible to perform imaging and dose estimation of the compound prior to the treatment. As the radiation is not restricted to the targeted cell, it may also affect all tumor cells in its range, for example, electrons, typically a few millimeters from the directly targeted cell. This effect, called 'bystander' or 'crossfire effect', is particularly important for treatment of tumors with a heterogeneous antigen or receptor expression or insufficient vascularization [2 ] . The most common nuclides that are currently used for endoradiotherapy are b-emitters such as Advanced prostate cancer is attractive for RIT as metastases from prostate cancer are almost exclusively located in bone marrow and lymph nodes (good access to circulating antibodies) and the metastases are often small enough to ensure good antibody penetration [27, 28] . Goldenberg et al. [29] were the first to demonstrate that a prostate-associated marker could be targeted and imaged by antibodies labeled with radionuclides. Later Meredith et al. [30] treated prostate cancer patients with 131 I-labeled CC49 monoclonal antibodies to TAG 72. Six of 10 symptomatic patients had bone pain relief, but no patients met the radiographic or PSA criteria for objective response. Positive imaging of bone and/or soft-tissue lesions was noted for 13 of the 15 patients.
Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein, which is expressed by nearly all prostate cancers and their metastases [27] . PSMA is upregulated in poorly differentiated and advanced prostate cancer. PSMA is not secreted like PSA, which makes PSMA an excellent target in prostate cancer. The first commercial antibody against PSMA was 7E11, which is used in 111 In-CYT-356 (ProstaScint, EUSA Pharma, Princeton, New Jersey, USA) -a Food and Drug Administration (FDA)-approved imaging agent for evaluation of metastatic prostate cancer [27] . In two trials, CYT-356, labeled with 90 Y, had no therapeutic effects in prostate cancer patients [31, 32] . This lack of therapeutic efficacy is due to the fact that 7E11 antibody targets an intracellular epitope of PSMA and therefore binds only to permeabilized, necrotic cells. This observation led to the development of the monoclonal antibody J591, which specifically targets epitopes located on the external domain of PSMA [33] . Thus, J591 binds to both intact and permeabilized cells. J591 labeled with radionuclides has been tested in in-vitro, in-vivo, and recently in clinical trials [34] [35] [36] [37] [38] [39] [40] 41 ,42].
In RIT, myelotoxicity due to bone marrow radiationabsorbed doses (BM rad ) is frequently the dose-limiting factor that determines the maximum tolerated dose (MTD). In a dose-escalation study by Vallabhajosula et al. [39] , 28 patients with prostate cancer received either 90 Y-labeled or 177 Lu-labeled J591 antibodies for RIT. It was demonstrated that myelotoxicity after treatment with 177 Lu-J591 could be predicted on the basis of the amount of radioactive dose administrated or the BM rad . However, there was no correlation between myelotoxicity and 90 Y-J591 dose. This may be explained by the fact that the crossfire effect of high-energy b-particles within the bone and the marrow may deliver radiation doses nonuniformly within the bone marrow. Alternatively, 90 Y-J591 may be less stable than 177 Lu-J591 in vivo and, as a result, higher amounts of free 90 Y may be localized in the bone. In a phase I trial, Bander et al. [42] found the MTD of 177 Lu-J591 to be 70 mCi/m 2 in a study including 35 patients with progressing androgen-independent prostate cancer. Multiple doses of 30 mCi/m 2 were well tolerated and excellent targeting of known sites of prostate cancer metastases was shown in the study. In a recent study by Pandit-Taskar et al.
[41 ], 14 patients with metastatic prostate cancer received escalating doses of 111 In-J591 in a series of administrations each separated by 3 weeks. In these 14 patients, a total of 80 lesions were detected. Both skeletal and soft-tissue metastases were targeted by the antibody as seen on 111 In-J591 scans. The antibody localized 93.7% of bone lesions detected by conventional imaging. The results from this study indicate that the optimal antibody mass for RIT may be greater than or equal to 50 mg. Recently, Tagawa et al. [43] found in a phase II trial that a single dose of 177 Lu-J591 was well tolerated, with reversible myelosuppression and demonstrated antitumor activity in patients with progressive metastatic castrate-resistant prostate cancer. Excellent targeting of known sites of metastases was seen in 31 of 32 (97%) patients, with trend for better response with more intense imaging.
Other tumor antigens such as HER2, CA 170, L6, and E4 antigen may also serve as targets for RIT in prostate cancer [27] . Overexpression of the HER2 receptor protein and amplification of the HER2 gene have been implicated in tumor development and progression and associated with a poor prognosis in several types of cancers [44 ] . In prostate cancer patients, HER2 expression is associated with disease progression and androgen independence [45, 46] . Furthermore, preoperative plasma HER2 levels are associated with prostate cancer progression after radical prostatectomy and predict for aggressive outcome after chemotherapy [45, 47 ]. Therefore, HER2 imaging and treatment with HER2-specific antibodies, unconjugated or labeled with radionuclides for RIT, has become an attractive therapeutic option for castration-resistant prostate cancer patients. De Bono et al. [48] found HER2 inhibitor pertuzumab to be ineffective in an open phase II study including patients with castration-resistant prostate cancer. There may be several explanations why pertuzumab was ineffective in this study, including insufficient target inhibition at the dose levels used, limited dependence of the treated tumors on HER2 signaling, differences in drug penetration to various HER2-expressing tumors, and the unknown HER2 status of the patients (immunochemistry, serum level, etc.) prior to treatment.
There is increasing evidence that small nonimmunoglobulin-based tracers have the best potential for the development of high-contrast imaging agents for visualization of HER2 in vivo as compared with whole fulllength monoclonal antibodies. Affibody molecules are a new class of relatively small proteins based on a 58-amino-acid scaffold, derived from the B domain of Staphylococcus aureus protein A. Combinatorial randomization of 13 amino acids in the binding site of that scaffold leads to creation of Affibody library containing 3 billion members, each characterized by a unique amino acid composition determining binding to the unique target structures. The specific binders can be identified by the phage display selection method. Their small size (Affibody molecules are 20 times smaller than antibodies) and high specificity make them ideal candidates for imaging purposes allowing for rapid blood clearance and good tumor penetration. Furthermore, the lack of sulfite bridges and high stability facilitate the conjugation chemistry [44 ] . Recently, Kramer-Marek et al. [49 ] have radiolabeled a HER2-binding Affibody molecule with 18 F for in-vivo monitoring of HER2 expression by PET. The same tracer was then used to assess the changes in HER2 expression following therapeutic intervention [50 ] . PET imaging of HER2 has also been found promising by Cheng et al. [51 ] in a xenograft tumor Lu for radionuclide therapy of HER2-positive microxenografts, a promising approach for treatment of micrometastases by HER2-expressing malignant tumors. Puri et al. [54] have recently used nanoparticles, that is, thermosensitive liposomes conjugated with Affibody molecules (Affisomes) as vehicles for HER2-specific delivery of therapeutic agents. Affisomes present a promising, novel strategy for HER2-specific drug delivery that could be used to improve the treatment of HER2-positive tumors. Although major challenges must be addressed (further clinical development of Affibody molecule-based imaging agents, optimization of clinical protocols regarding amount of tracer injected, radioactivity, imaging time, etc.), HER2 represents an attractive target for PET/CT and RIT of HER2-expressing tumors. At present, the main role of HER2 imaging is to select patients who would benefit from anti-HER2 therapy with trastuzumab [44 ] . HER2 imaging may also have the potential to predict for response to therapy, to evaluate the effect of a given therapy, and to detect recurrence of disease.
Conclusion
Today's molecular imaging technologies aim to provide early and accurate detection of cancers at initial presentation and following therapeutic interventions. Advances in imaging techniques may lead to early prostate cancer detection, more accurate tumor staging, better monitoring of the disease, and early and accurate detection of recurrence. The role of PET/CT in prostate cancer is still being established, especially in the detection of recurrences and bone metastases. As no effective therapies are available for advanced metastatic disease, there is a need for new treatment modalities. Prostate cancer is well suited for molecular imaging and RIT, leading to the development and clinical evaluation of therapeutic monoclonal antibodies and engineered affinity proteins directed to targets in prostate cancer. 
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